North America Biosimilars Market Outlook, 2030

Market Dynamic

Market Drivers

• Patent Expirations of Biologic Drugs: One of the primary drivers of the North American biosimilars market is the wave of patent expirations for major biologic drugs. Blockbuster biologics such as Humira (adalimumab), Remicade (infliximab), and Enbrel (etanercept) have faced or are approaching the end of their exclusivity periods. As these patents expire, opportunities open up for biosimilar manufacturers to introduce more affordable alternatives. The legal and regulatory framework, especially the Biologics Price Competition and Innovation Act (BPCIA) in the U.S., supports this transition by providing a clear pathway for biosimilar approval.
• Increasing Demand for Cost-effective Treatments: Healthcare systems across North America, especially in the United States and Canada, are under pressure to reduce spending while maintaining high-quality patient care. Biosimilars offer a promising solution by providing cost-effective alternatives to expensive biologics used to treat chronic conditions such as cancer, autoimmune diseases, and diabetes. With the rise in chronic disease prevalence and an aging population, the demand for affordable therapies is growing. Payers, including insurance companies and government programs like Medicare and Medicaid, are increasingly incentivizing or mandating the use of biosimilars to help manage healthcare budgets.

Market Challenges

• Physician and Patient Skepticism: Despite regulatory approvals, many physicians and patients remain cautious about switching from originator biologics to biosimilars. Concerns revolve around the efficacy, safety, and immunogenicity of biosimilars, even though they are highly similar to the reference products. This skepticism can be attributed to a lack of familiarity, limited real-world evidence, and the historical perception that biosimilars are not equivalent to generics. Overcoming these concerns requires continuous education, robust post-marketing surveillance, and transparent communication from manufacturers and regulators to build trust in the biosimilar landscape.
• Regulatory and Market Access Barriers: The regulatory environment for biosimilars in North America, while evolving, still poses challenges. The U.S. Food and Drug Administration (FDA) has made strides in establishing pathways for approval, but the complexity of biologic drugs makes biosimilar development more difficult and costly than for traditional generics. Additionally, gaining market access can be difficult due to entrenched relationships between providers and original biologic manufacturers, rebate strategies that favor originators, and formulary exclusions. These hurdles can delay market entry and limit the competitive impact of biosimilars.

Market Trends

• Rising Interchangeability Designations: A growing trend in the biosimilars market is the push for interchangeability designations by the FDA. An interchangeable biosimilar can be substituted for the reference product at the pharmacy level without physician intervention, much like generic drugs. Achieving this status requires additional studies to demonstrate that the switch between the biosimilar and the reference product does not impact safety or efficacy. More biosimilars are pursuing this designation as it can significantly enhance uptake and acceptance, particularly in retail and outpatient settings. As more products earn interchangeability, the market is likely to see broader adoption and increased competition.
• Strategic Collaborations and Partnerships: Pharmaceutical companies are increasingly forming strategic alliances to develop, manufacture, and distribute biosimilars. These collaborations help share the high costs and technical complexities associated with biosimilar development. Partnerships between big pharma and specialized biosimilar developers, as well as between Western and Asian firms, are becoming more common. Such alliances accelerate product pipelines, improve market access, and foster innovation in manufacturing processes. This trend indicates a maturing market where stakeholders recognize the long-term value and sustainability of biosimilars in North America.